Core Viewpoint - The company has received a medical device registration certificate for its new generation folic acid testing kit, which enhances its competitiveness in the anemia detection market [1] Group 1: Product Development - The company announced the receipt of a registration certificate from the Guangdong Provincial Drug Administration for the folic acid testing kit, classified as a Class II medical device [1] - The product is designed for the quantitative measurement of folic acid levels in human serum or plasma samples, aiding in the diagnosis of megaloblastic anemia [1] - The new testing kit utilizes a sandwich chemiluminescence immunoassay method, improving sensitivity and precision [1] Group 2: Market Position - The company and its subsidiaries have obtained 106 registration certificates for chemiluminescence detection reagents, enhancing the testing menu for its chemiluminescence project [1] - This expansion is expected to strengthen the company's market competitiveness in the immunodiagnostics field [1] Group 3: Future Outlook - The actual sales performance of the product post-launch will depend on future market promotion efforts, and the specific impact on the company's future performance remains unpredictable [1]

Core Viewpoint - The company has received a medical device registration certificate for its new product, a folic acid assay kit, which enhances its market competitiveness in the anemia detection field [1] Group 1: Product Development - The company has obtained the registration certificate from the Guangdong Provincial Drug Administration for the folic acid assay kit, classified as a Class II medical device, with a registration number valid until December 18, 2030 [1] - The folic acid assay kit is designed for the quantitative measurement of folic acid levels in human serum or plasma, aiding in the diagnosis of megaloblastic anemia [1] - This new generation product utilizes a sandwich chemiluminescent immunoassay method, improving the sensitivity and precision of the assay [1] Group 2: Market Position - The company and its subsidiaries have secured a total of 106 registration certificates for chemiluminescent assay kits, further enriching its testing menu in the immunodiagnostic field [1] - The advancements in product offerings are expected to enhance the company's competitiveness in the immunodiagnostic market [1] Group 3: Sales and Market Impact - The actual sales performance of the newly launched product will depend on future market promotion efforts, and the specific impact on the company's future performance remains unpredictable [1]